Condition: Advanced Prostate Adenocarcinoma · Sponsor: Veru Inc.
To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Arizona Urology Specialist | Tucson, Arizona, United States | — |
| Urology Associates of Southern Arizona | Tucson, Arizona, United States | — |
| San Bernardino Urological Associates | San Bernardino, California, United States | — |
| Genesis Research, LLC | San Diego, California, United States | — |
| Debbie Urology Johnson | Jeffersonville, Indiana, United States | — |
| Chesapeake Urology Research Associates | Towson, Maryland, United States | — |
| Clinical Research Solutions | Middleburg Heights, Ohio, United States | — |
| MidLantic Urology | Bala-Cynwyd, Pennsylvania, United States | — |
| Carolina Urologic Research Center | Myrtle Beach, South Carolina, United States | — |
| Houston Metro Urology | Houston, Texas, United States | — |
| Urology San Antonio | San Antonio, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04843319